Goals for the future
As we look ahead, we have set ambitious goals to ensure that patients across Europe receive the highest quality care and support. Our future plans are centered around expanding our network, enhancing research capabilities, and fostering innovative treatments for rare vascular diseases. At VASCERN, our commitment to improving the lives of patients with rare vascular diseases is unwavering.
Our goals for the future
1. Expanding Coverage Across Europe: Our primary goal is to ensure that all patients in the European Union (EU) have access to specialized care for rare vascular diseases. We aim to include healthcare professionals and expert centers in every EU country. This involves establishing new collaborations and partnerships with healthcare providers throughout Europe to bridge geographical gaps in care. By doing so, we can ensure that no patient is left without appropriate diagnosis, treatment, or follow-up care.
2. Establishing European Registries To advance our understanding of rare vascular diseases, we are dedicated to creating European registries. These registries will systematically collect and store data from patients across the EU, offering valuable insights into the prevalence, natural history, clinical manifestations, and treatment outcomes of these conditions. Consolidating data from diverse sources will facilitate research, support evidence-based decision-making, and ultimately improve patient care on a pan-European scale.
3. Supporting Research Projects Research is crucial for developing new treatments and improving outcomes for patients with rare vascular diseases. VASCERN actively supports and promotes research projects focused on these conditions. We encourage collaboration among clinicians, researchers, and patient organizations to foster innovative, interdisciplinary approaches to tackling the challenges posed by rare vascular diseases. Through these efforts, we aim to discover new therapeutic targets and enhance our understanding of the underlying mechanisms of these diseases.